

ANABOLIC STEROIDS: A REVIEW OF THEIR EFFECTS ON THE MUSCLES, OF THEIR POSSIBLE MECHANISMS OF ACTION AND OF THEIR USE IN ATHLETICS

F CELOTTI* and P NEGRI CESI

Department of Endocrinology, University of Milano, Via Balzaretti 9, 20133, Milano, Italy

Summary—Anabolic steroids are synthetic molecules developed in the hope of obtaining a complete separation of the androgenic and myotrophic (anabolic) actions of testosterone. Such a goal has never been fully achieved. However, some synthetic steroids present a partial dissociation between these two activities. Since a single hormonal receptor apparently mediates the androgenic as well as the anabolic actions of testosterone, differences in patterns of androgen metabolism in the muscles and the sex accessory organs have been proposed as a possible cause of this phenomenon. Undoubtedly, androgens are able to exert a trophic effect on skeletal and cardiac muscle fibres in subjects with low circulating levels of testosterone such as prepubertal or hypogonadal males and females, however, the widespread use of anabolic steroids in male athletes to increase their physical performances poses the question of whether these compounds are active in the presence of normal circulating levels of testosterone. Most experimental animal studies indicate that anabolic steroids are ineffective in this situation. Since the results of the experiments performed in humans are largely contradictory, it is still not clear whether anabolic steroids are able to improve athletic performances. These and other relevant issues are reviewed.

INTRODUCTION

Testosterone, the main testicular steroid hormone, exerts specific as well as trophic effects on a wide variety of central and peripheral androgen-dependent or -sensitive structures. These include the sex accessory organs, the central nervous system, the anterior pituitary, the kidney, the liver, the muscles, etc. Since the musculature contributes more than one third of the body mass, the myotrophic action of testosterone is specifically responsible for the retention of nitrogen, usually defined as the anabolic effect of the hormone.

In adult animals testosterone exerts a trophic effect on skeletal and cardiac muscle fibres, since castration produces atrophy and testosterone administration hypertrophy of individual fibres without changing the number of myofibrils (see [1] for a review). However, rarely if ever, the trophic action of the exogenous hormone is more pronounced than that achieved by normal circulating levels of testosterone, this will be discussed later in more detail. On the

other hand, testosterone stimulates the mitotic activity in a myoblast culture system [2] and, when given to female rats before the 7th day of postnatal life, produces a significant increase in the number of fibres of the levator ani muscle, without affecting the cross-sectional area [3]; on the contrary, after the 7th day of life only an increase in the average cross-sectional area was observed [3]. The developmental action of testosterone on this muscle is apparently a direct action of the hormone on the myofibrils, which already possess androgen receptors, and it is not mediated by the influence of testosterone on the spinal nucleus innervating these muscles, the sexual dimorphism of which is a consequence of the different number of myofibrils existing in the two sexes [4].

The response to androgens is different among the animal species and among the various muscle groups. In the guinea pig, those from the shoulders, back and head show a greater sensitivity to the androgenic action than those of the chest and the hind legs [1]. Also in man, the muscles of the pectoral and shoulder region appear to possess a higher androgen sensitivity (see [5] for a review).

A particular mention should be made of the androgen-dependent, sexually dimorphic,

Proceedings of the XV Meeting of the International Study Group for Steroid Hormones, Rome, Italy, 28-30 November 1991

*To whom correspondence should be addressed

perineal muscles of the rat and of the guinea pig the levator ani, the bulbocavernosus and the ischiocavernosus which have been considered a model for testing the relative myotrophic-androgenic activity ratio of steroids since they possess a higher sensitivity to androgens than the other skeletal muscles. This ratio, often called the myotrophic-androgenic index [6], has been usually evaluated in castrated immature male rats treated with different steroids as the ratio between the weight of the levator ani-bulbocavernosus complex (BCLA) and that of the ventral prostate and/or of the seminal vesicles [6-8]. However, the validity of the test has often been questioned, because the perineal muscles cannot be considered real extragenital organs [9]. It will appear, in the discussion which follows, that the peculiar androgen sensitivity and sexual dimorphism of the perineal muscles is probably due to their receptorial and metabolic profile, which is intermediate between those present respectively in the skeletal muscles and in sex accessory organs.

Although not well defined so far, the hypertrophic action of testosterone and other androgens on the muscle fibers is the consequence of an increase in protein synthesis [10]. Boissonneault *et al* [11] have indeed described following gonadectomy in the rat, a progressive decrease of muscle weight and methionine incorporation, as well as of polyribosome translational efficiency, these effects can be reverted by the administration of testosterone propionate.

Androgens also directly stimulate some biochemical parameters related to energy metabolism, like, for instance, the uptake and phosphorylation of glucose [12] and the synthesis of glycogen [13]. In conclusion, there is no doubt that androgens exert a clear-cut effect on the muscles, which is apparent in females, in developing or hypogonadal animals, and appears to be mediated by the activation of androgenic receptors.

ANABOLIC STEROIDS: BIOCHEMICAL STUDIES

Since the initial studies of Kochakian, which proposed the possibility to dissociate the anabolic from the androgenic effects of androgens, more than 600 molecules, the structure of which was mainly derived from that of testosterone, have been synthesized, particularly between the 50s and 60s, in the search for a compound exerting a pure anabolic action (see [6-8] for reviews). Such a

compound has never been found, however, some synthetic steroids present a remarkable dissociation between the anabolic and the androgenic activities, at least on the basis of the myotrophic-androgenic index [6, 7]. On the other hand, it must be underlined that all anabolic steroids, when used in adequate doses and for prolonged periods of time, lose the dissociation of these two pharmacodynamic activities, and can be used in the treatment of hypogonadism [5].

Which mechanism(s) might explain the partial dissociation of the anabolic and androgenic effects exerted by synthetic anabolic steroids?

The first question which can be asked is whether the androgenic receptors in the skeletal muscle differ from those found in classical androgen-dependent structures (e.g. prostate and seminal vesicles). Binding studies performed in several laboratories clearly indicate that the androgenic receptors in the skeletal or cardiac muscle possess the same binding affinity and biochemical characteristics of those present in the sex accessory organs [1, 14, 15]. Moreover the binding affinities of muscle and prostate androgenic receptors for the anabolic steroids studied so far, do not show significant differences [16, 17]. The identity of the two theoretical classes of receptors (anabolic vs androgenic) has been also indirectly confirmed by some *in vitro* studies [18], in which receptors isolated from the cytosol of rat prostatic glands can be easily translocated to nuclei of the cardiac muscle, where they bind to the chromatin. Finally, recent immunocytochemical studies performed in rat, mouse and man with mono- and poly-clonal antibodies against the N-terminal domain of the androgen receptor, have indicated the immunological identity of the skeletal and cardiac muscle receptors with those of the prostate and of the brain [19].

However, at variance with these studies, Ruizeveld De Winter *et al* [20], utilizing different mono- and poly-clonal antibodies, always directed to the N-terminal domain of the androgen receptor, failed to identify a positive immunostaining in human skeletal muscle nuclei, while a low intensity nuclear androgenic receptor expression was found in myocardial biopsies from 2 male patients, but not in the corresponding specimens from 2 female patients. It is possible that these negative findings might be due to the low level of receptors present in the muscle cells. As a matter of fact, comparative binding studies performed in

the rat indicate that the number of binding sites/mg of protein are 60 times lower in the skeletal muscle than in the prostate, while in BCLA they are only 7 times less than in the prostate [14] Moreover the B_{max} values (an index of the number of binding sites) calculated for the cytosol of the human skeletal muscle are about 10-fold lower than those of normal or hyperplastic human prostate [21]

On the basis of the findings quoted above, it might be possible to conclude that the dissociation of the androgenic-anabolic properties of hormonal steroids cannot be due to the presence, in the muscles, of receptors different (or with different binding properties) from those present in the reproductive structures, it emerges, however, that the amounts of receptors present in the muscles are much lower than those found in the reproductive sex organs This finding may explain the relative low sensitivity of the skeletal muscles to androgens

The next question which can be asked is the following does the androgen metabolic pattern of the muscle explain the partial dissociation of the anabolic and androgenic effects?

It is well known that in the reproductive structures and in the brain testosterone does not act in its original molecular conformation, but it is locally transformed into active metabolites through the action of two different enzymes the 5α -reductase and the aromatase [22–24] The 5α -reductase converts testosterone into dihydrotestosterone (DHT), which can be further metabolized into 5α -androstane- $3\alpha,17\beta$ -diol (3α -diol) by a 3α -hydroxysteroid-dehydrogenase The conversion of testosterone to DHT is irreversible, while the conversion of DHT to 3α -diol is reversible in most of the tissues, with a notable exception the muscle [25] The aromatase catalyzes the irreversible transformation of testosterone into estrogenic molecules In male subjects, the 5α -reductive pathway is present in almost all the androgen-dependent structures [22–24], whereas the aromatase has been demonstrated and characterized only in the brain [23, 26], in the adipose tissue [27] and in the testes [28] Its presence in the prostate is still controversial [29, 30] The heart and skeletal muscle seem to possess a low activity of this enzymatic complex [31, 32]

Due to the multifactorial metabolic pattern described above, the androgenic signal can be amplified or modulated within the target cells through the interaction of the various testosterone metabolites with different receptors While

the aromatization of androgens into estrogens produces compounds acting through the estrogenic receptor, the 5α -reduction of testosterone into DHT produces a compound possessing a binding affinity for the androgenic receptor 2 to 6 times higher than that of testosterone In this case the metabolic transformation is a mechanism of amplification of the androgenic signal, which is necessary to produce and maintain the normal development and trophism of peripheral androgen-dependent structures, as, for example, the prostate [33–35] Among the androgen-sensitive tissues, the muscle is one of the few structures in which the 5α -reductase is very low or absent Massa and Martini [36] have indeed found that, the *in vitro* formation of 5α -reduced steroids is virtually absent in the skeletal muscle and in the levator ani of the male rat The presence of a very low 5α -reductase activity in the skeletal muscle of the rat was subsequently confirmed by other authors [37, 38] In these studies, however, the enzymatic activity of the BCLA appears to be significantly higher than that present in the skeletal and cardiac muscles, even if it represents only 5% of that present in the prostate Therefore, as in the case of the receptor content, the testosterone metabolic pattern of BCLA also appears to be intermediate between that of the prostate and skeletal muscles

It is noteworthy that, in the muscles (both in the skeletal and heart muscles, and in the BCLA), there is a high activity of the enzyme 3α -hydroxysteroid-dehydrogenase [25, 36] converting DHT into 3α -diol, a compound which does not bind to the androgenic receptor [17] The enzyme is cytosolic, NADPH-dependent and is apparently unable to catalyze the back-conversion of 3α -diol to DHT, moreover, it possesses a higher activity in females and in castrated males [25] Consequently, in the muscles, intracellular DHT is low, not only because of the low 5α -reductase activity, but also because the 3α -hydroxysteroid-dehydrogenase further metabolizes this steroid to 3α -diol, which, as previously said, cannot revert back to DHT Moreover, 3α -hydroxysteroid-dehydrogenase helps to maintain low intracellular concentrations of DHT by inactivating the amounts of this steroid reaching the muscle cells from the circulation

Little is known on the role of aromatization in muscular function estrogen receptors have been identified in the rat and bovine muscles [39, 40], and a possible role of the




Fig 1 5 α -Reductive metabolism of testosterone and of the anabolic steroid nandrolone

formation of estrogens in the control of glucose 6-phosphate dehydrogenase in the rat levator ani has been proposed [41]. However, no clinically evident alterations of muscular function have been noted during prolonged treatments with antiestrogens or aromatase inhibitors [42, 43].

It is therefore likely that testosterone exerts its effects on muscle cells acting in its native molecular form. This metabolic characteristic, which distinguishes the muscles from the other androgen-dependent or -sensitive tissues, could help to explain the partial dissociation of the myotrophic from the androgenic actions in some anabolic steroids (see below).

Among the great number of anabolic molecules synthesized, 19-nortestosterone (nandrolone) is one of the first discovered, the most used and indeed the best studied. When administered to castrated male rats, it appears to be 5 times more active in increasing levator ani than seminal vesicle weight [7]. Nandrolone is as good a substrate for the 5 α -reductase as testosterone [44] and the main metabolite of this reaction is 5 α -dihydro-19-nortestosterone (DHN) (Fig 1). The relevant finding is that the 5 α -reduction of nandrolone (at variance with what happens for testosterone) does not result in the amplification of the hormonal signal [45–47]. Figure 2 shows the conversion of testosterone into DHT which is associated with an increase in the binding affinity of the reduced steroid to the androgen receptor, on the contrary, the 5 α -reduction of nandrolone (a compound which itself binds to the prostatic androgenic receptor with an affinity higher than that of testosterone) pro-

duces a metabolite possessing a lower binding affinity than that of the parent compound. These *in vitro* results might explain the different *in vivo* nuclear retentions of testosterone, nandrolone and their 5 α -reduced metabolites in the prostate, in the skeletal and levator ani muscle of rats, after a continuous infusion of comparable amounts of testosterone or nandrolone (Fig 3). As hypothesized by Tooth and Zakar [45], it is possible that the simultaneous presence in the molecular structure of a 4-ene double bond and of a 19-methyl group results in a steric structure which presumably does not accurately fit the steroid binding domain of the receptor, once one of these chemical features is eliminated (by 5 α -reduction or by the removal of the 19-methyl group), the molecule increases its binding affinity, however, when both these modifications are present, as in the case of 5 α -dihydro-19-nortestosterone, the affinity becomes low. These *in vitro* and *in vivo* studies might




Fig 2 Relative binding affinities of testosterone (T), DHT, nandrolone (N) and dihydro-19-nortestosterone (DHN) to the androgenic receptor of the rat prostate measured *in vitro* (Data from Ref [46])

explain the prevalent myotrophic effect of nandrolone the 5α -reduction of the drug, occurring in the prostate with high yields, leads to a compound which has a lower affinity and nuclear retention than DHT, and which therefore exerts a relatively low androgenic effect. On the other hand, in the muscles, where the 5α -reductase is low, nandrolone possesses a higher affinity than testosterone for the androgenic receptor, leading to a relatively strong myotrophic action.

Obviously, the mechanism of the anabolic action proposed for nandrolone cannot be generalized, since not all the anabolic steroids are good substrates for the 5α -reductase as, for example, methanediene [48]. Moreover, to the authors' knowledge, the metabolism of the anabolic steroids and the binding affinity of the metabolites to the androgenic receptor have been studied in detail only in the case of nandrolone. However, it is interesting to note that some steroids with anabolic-androgenic activity *in vivo* do not bind *in vitro* to the androgenic receptor, as for example does oxymetholone and ethylestrenol [17]. An indirect mechanism of action possibly via their biotransformation into active compounds should be postulated in these cases.

ANABOLIC STEROIDS: EFFECTS IN ANIMALS

The classical therapeutic uses of androgens and of the anabolic steroids are linked to the correction of male hypogonadism, to the treatment of hereditary angioneurotic edema and to the stimulation of erythropoiesis and of bone mineralization [49]. Unfortunately these drugs are also used by athletes in the hope of improving their muscular mass or their physical performance. Androgens are undoubtedly able to




Fig 3 Nuclear retention of testosterone (T), DHT, nandrolone (N) and dihydronandrolone (DHN) in the prostate, levator ani and skeletal muscle of the rat after a continuous infusion of labelled T or N (Data from Ref [46])

Table 1 Negative experimental results in animals

Supraphysiological doses of androgens administered to rats do not produce additional muscle growth beyond that expected for physiological levels of testosterone [53]
The anabolic steroid stanzolol has no effect on the body weight, muscle growth and protein metabolism in normal well-fed male rats [54]
Testosterone administration does not alter the biochemical parameters related to energy metabolism in the rat gastrocnemius [55]
Testosterone implants do not produce synergistic effects on compensatory muscle hypertrophy (muscle weight and oxidative capacity) in normal male rats [50]

increase muscle mass in subjects with low circulating levels of testosterone such as prepubertal or hypogonadal males and females. However, their actual effectiveness in producing synergistic effects with those of exercise has been challenged, since the castration of male rats [50] or chronic treatment with testosterone of female rats [51, 52] does not affect the compensatory hypertrophy of the plantaris muscle or its oxidative capability, after the removal of its synergistic muscles.

Most of the results obtained in normal male animals (Table 1) substantiate the hypothesis that the administration of supraphysiological doses of androgens does not exert remarkable effects on the skeletal muscle. Moreover, it is noteworthy that the number of androgenic receptors appears to be down-regulated by testosterone and other androgens, since castration of male rats and sheep produces an increase in receptor number without affecting their affinity [56, 57].

Anabolic steroids, however, appear to exert some positive effects in normal male animals on some aspects of protein and energetic metabolism of the muscles (Table 2).

ANABOLIC STEROIDS: EFFECTS IN HUMANS

In humans, most studies on the effects of anabolic steroids on muscle strength or mass have been performed in athletes. It is rather

Table 2 Positive experimental results in animals

Utilizing the ^{15}N -tracer technique it has been shown a positive influence of androgens and of androgens + training on protein synthesis in the rat [58]
Methanediene treatment in combination with physical exercise increases myofibrillar protein concentration [59]
Anabolic steroids can affect mitochondrial and sarcotubular enzymes in skeletal muscle of the male rats [60]
Anabolic steroids increase the activity of the enzyme carnitine palmitoyltransferase in mitochondrial outer membrane of fast-twitch muscles of male rats. The enzyme plays an important role in regulating the flux of long-chain fatty acids to mitochondrial oxidative metabolism [61]

surprising that, after many years of use and abuse, it is still not clear whether anabolic steroids are able to improve athletic performances. The difficulty in carrying out properly designed studies constitutes the reason for this uncertainty. The number of controlled trials in which the administration of anabolic steroids was ineffective [62–72] is almost equal to those in which slight effects on muscle strength or mass have been shown [73–83].

Many experimental differences make it difficult to reach a unitary interpretation of the results: (a) the studies usually include a limited number of subjects and they are not always blinded or blinding has been broken because of the side-effects of the drugs, (b) different steroids have been given in different doses (which are usually much lower than those utilized when the drugs are self-administered), (c) the lengths of the experimental periods are usually relatively short (3–4 weeks), particularly in placebo-controlled studies, (d) different training programs during and before the study, different assessment criteria, and different diets have been used, and (e) placebo effects or the increased aggressiveness reported by many steroid-users might have affected strength measurements.

Despite the inconsistent results of the literature, some recent papers and reviews [84–88] maintain that significant improvements in athletic performances can be observed if the following criteria are met: (1) steroid administration in previously trained athletes during intense training, (2) supplementation with high-protein, high-caloric diets, (3) utilization of very sensitive techniques of strength measurements (multiple-joint, single-repetition, maximal-weight techniques), and (4) administration of high doses of steroids for very prolonged observation times (for instance, significant effects appeared after 4–5 months of administration plus training in the study of Alen and Hakkinen [85]).

This opinion is in substantial agreement with that of the American College of Sports Medicine which in the position stand [89] states that anabolic steroids can result in small but significant increases in strength in some but not all individuals.

It is the view of the authors that, if an effect of the anabolic steroids on the muscle mass or physical performance in eugonadal male subjects exists, it is very small and still lacks a straightforward demonstration. However, if we assume that such an effect exists, what are the possible mechanisms of action?

In normal adult men, the concentration of testosterone in the blood is 3 to 10 times and that of DHT is 1 to 3 times the respective K_d for the androgenic receptor; in this situation, it is likely that the androgenic receptor system is almost completely saturated by the circulating steroids. The androgen receptor is therefore probably not involved in the action of the anabolic steroids in these subjects. It is then possible that anabolic steroids exert their action on several other parameters. They might antagonize the increased protein breakdown during the muscular stress of athletic training (see below), they might increase fluid and electrolyte retention, producing an increase in body weight [5], they might induce a faster recovery after strenuous exercise as suggested by lower circulating lactate [90] and creatine kinase levels in anabolic users [91], or they might produce psychological effects (increased aggressiveness, euphoria and diminished fatigue) which might facilitate the training and help in competitive performances [5, 64].

Finally, it should be remembered that recent studies have identified rapid effects exerted by androgens on the skeletal [92] and heart muscle [93]. These effects are still poorly characterized and may involve the action of androgens on membrane receptors present in motoneurons [92] or directly on the myocytes [93]. In cultured cardiac myocytes, for example, testosterone may induce a transient accumulation of polyamines which apparently serve as intracellular messengers to regulate transmembrane calcium movements [93]. The involvement of membrane effects of androgens in muscle physiology is purely speculative at this point. The existence of an anticatabolic effect, proposed by many authors as the main mechanism of action of anabolic steroids, is rather controversial. The field has been recently reviewed by Hickson *et al* [94]. According to some authors, the muscle atrophy induced by corticosteroids may be retarded by anabolic steroids, however, other authors disagree. Moreover, the binding studies performed *in vitro* and *in vivo* are also contradictory: a very low binding affinity of anabolic agents to the glucocorticoid receptor has been shown in some studies, while others have underlined more significant cross-binding of anabolic steroids to the glucocorticoid receptor.

In conclusion, it appears that the effectiveness and the possible mechanism(s) of action of anabolic steroids on the muscle of eugonadal

subjects are still open to discussion, unfortunately, it clearly appears from the literature that the continuous administration of high doses of anabolic steroids produces a large number of side-effects some of which are serious, irreversible and possibly life-threatening [5, 95–99]

REFERENCES

- Mooradian A D, Morley J E and Korenman S G Biological actions of androgens *Endocrine Rev* **8** (1987) 1–28
- Powers M L and Florini J R A direct effect of testosterone on muscle cells in tissue culture *Endocrinology* **97** (1975) 1043–1047
- Tobin C and Joubert Y Testosterone-induced development in the rat levator ani-muscle *Dev Biol* **146** (1991) 131–138
- Fishman R B, Chism L, Firestone G L and Breedlove S M Evidence for androgen receptors in sexually dimorphic perineal muscles of neonatal male rats: absence of androgen accumulation by the perineal motoneurons *J Neurobiol* **21** (1990) 694–704
- Wilson J D Androgen abuse by athletes *Endocrine Rev* **9** (1988) 181–199
- Kruskemper H L *Anabolic Steroids* Academic Press, New York (1969)
- Vida J A *Androgens and Anabolic Agents Chemistry and Pharmacology* Academic Press, New York (1969)
- Kopera H The history of anabolic steroids and a review of clinical experience with anabolic steroids *Acta Endocr* **110** (Suppl 271) (1985) 11–18
- Hayes K J The so-called 'levator ani' of the rat *Acta Endocr* **48** (1965) 337–347
- Breuer C B and Florini J R Effects of ammonium sulphate, growth hormone and testosterone propionate on ribonucleic acid polymerase and chromatin activities in rat skeletal muscle *Biochemistry* **5** (1966) 3857–3861
- Boissonneault G, Gagnon J, Ho-Kim M A, Rogers P A and Tremblay R R Depressed translational activity in the androgen sensitive levator ani muscle of the rat *J Steroid Biochem* **32** (1989) 507–513
- Max S R and Toop J Androgens enhance *in vivo* 2-deoxyglucose uptake by rat striated muscle *Endocrinology* **113** (1982) 119–126
- Bergamini E Different mechanisms in testosterone action on glycogen metabolism in rat perineal and skeletal muscles *Endocrinology* **96** (1975) 77–84
- Krieg M Characterization of the androgen receptors in the skeletal muscle of the rat *Steroids* **28** (1976) 261–274
- Snochowski M, Dahlberg E and Gustafsson J-A Characterization and quantification of the androgen and glucocorticoid receptors in cytosol from rat skeletal muscle *Eur J Biochem* **111** (1980) 603–616
- Dhalberg E, Snochowski M and Gustafsson J-A Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol *Endocrinology* **108** (1981) 1431–1440
- Saartok T, Dhalberg E and Gustafsson J-A Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscles and prostate, as well as to sex hormone-binding globulin *Endocrinology* **114** (1984) 2100–2106
- Krieg M, Smith K and Elvers B Androgen receptor translocation from cytosol of rat heart muscles, bulbocavernosus/levator ani muscle and prostate into heart muscle nuclei *J Steroid Biochem* **13** (1980) 577–587
- Takeda H, Chodak G, Mutchnik S, Nakamoto T and Chang C Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptors *J Endocr* **126** (1990) 17–25
- Ruizeveld De Winter J, Trapman J, Vermey M, Mulder E, Zegers N D and Van der Kwast T H Androgen receptor expression in human tissues: an immunohistochemical study *J Histochem Cytochem* **39** (1991) 927–936
- Snochowski M, Saartok T, Dhalberg E, Erkksson E and Gustafsson J-A Androgen and glucocorticoid receptors in human skeletal muscle cytosol *J Steroid Biochem* **14** (1981) 765–771
- Wilson J D and Gloyne R E The intranuclear metabolism of testosterone in the accessory organs of reproduction *Recent Prog Horm Res* **26** (1970) 309–336
- Martini L The 5 α -reduction of testosterone in the neuroendocrine structures: Biochemical and physiological implications *Endocrine Rev* **3** (1982) 1–25
- Celotti F, Melcangi R C and Martini L The 5 α -reductase in the brain: molecular aspects and relation to brain function *Frontiers Neuroendocr* **13** (1992) 163–215
- Smith K, Krieg M and Schwien S *In vitro* metabolism of 5 α -dihydrotestosterone to 5 α -androstane-3 α ,17 β -diol in rat heart, diaphragm, skeletal muscle and bulbocavernosus/levator ani: enzyme characterization and quantification *J Steroid Biochem* **13** (1980) 917–924
- Naftolin F, Ryan K J, Davies I J, Reddy V V, Flores F, Petro Z, Kuhn M, Whith R J, Takaoka Y and Wolin L The formation of estrogens by central neuroendocrine tissues *Recent Prog Horm Res* **31** (1975) 295–319
- Simpson E R, Merrill J C, Hollub A J, Graham-Lorence S and Mendelson C R Regulation of estrogen biosynthesis by human adipose cells *Endocrine Rev* **10** (1989) 136–148
- Payne A H, Perkins L M, Georgiou M and Quinn P G Intratesticular site of aromatase activity and possible function of testicular estradiol *Steroids* **50** (1987) 435–448
- Zoppi S, Negri-Cesi P, Lechuga M J and Motta M Effect of enzyme inhibitors and of LHRH analogs on androgen metabolism in the human prostate. In *Progress in Endocrinology* (Edited by H Imura, K Shizume and S Yoshida) Excerpta Medica, Amsterdam, Vol 1 (1988) pp 293–299
- Brodie A M H, Son C, King D A, Meyer K M and Inkster S E Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism *Cancer Res* **49** (1989) 6551–6555
- Matsumine H, Hirato K, Yanaiharu T, Tamada T and Yoshida M Aromatization by skeletal muscle *J Clin Endocr Metab* **63** (1986) 717–720
- Sholl S A, Goy R W and Kim K L 5 α -Reductase, aromatase, and androgen receptor levels in the monkey brain during fetal development *Endocrinology* **124** (1989) 627–634
- George F W and Peterson K G 5 α -Dihydrotestosterone formation is necessary for embryogenesis of the rat prostate *Endocrinology* **122** (1988) 1159–1164
- Grino P B, Griffin J E and Wilson J D Testosterone at high concentration interacts with the human androgen receptor similarly to dihydrotestosterone *Endocrinology* **126** (1990) 1165–1172
- Lubahn D B, Joseph D R, Sullivan P M, Willard H F, French F S and Wilson E M Cloning of human androgen receptor complementary DNA and localization to the X chromosome *Science* **240** (1988) 327–330
- Massa R and Martini L Testosterone metabolism: a necessary step for activity? *J Steroid Biochem* **5** (1974) 941–947

- 37 Krieg M, Dennis M and Voigt K D Comparison between the binding of 19-nortestosterone, 5 α -dihydrotestosterone and testosterone in rat prostate, and bulbocavernous/levator ani muscle *J Endocr* **70** (1976) 379–387
- 38 Bartsch W, Krieg M and Voigt K D Quantification of endogenous testosterone, 5 α -dihydrotestosterone and 5 α -androstane-3 α ,17 β -diol in subcellular fractions of the prostate, bulbocavernous-levator ani muscle, skeletal muscle and heart muscle of the rat *J Steroid Biochem* **13** (1980) 259–264
- 39 Dube J T, Lesage R and Tremblay R R Androgen and estrogen binding in rat skeletal and perineal muscles *Can J Biochem* **54** (1976) 50–56
- 40 Sauerwein H and Meyer H H Androgen and estrogen receptors in bovine skeletal muscle relation to steroid-induced allometric muscle growth *J Anim Sci* **67** (1989) 206–212
- 41 Knudsen J F and Max S R Aromatization of androgens to estrogens mediates increased activity of glucose 6-phosphate dehydrogenase in rat levator ani muscle *Endocrinology* **106** (1980) 440–443
- 42 Mouridsen H, Palshoff T, Patterson J and Battersby L Tamoxifen in advanced breast cancer *Cancer Treat Rev* **5** (1978) 131–136
- 43 Santen R J, Worgul T J, Samojlik E, Interrante A, Boucher A E, Allan Lipton C R N P, Harvey H A, White D S, Emma Smart R N, Cox C and Wells S A A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer *New Engl J Med* **305** (1981) 545–555
- 44 Tooth M and Zakar T Different binding of testosterone, 19-nortestosterone and their 5 α -reduced derivatives to the androgen receptor of the rat seminal vesicle a step toward the understanding of the anabolic action of nortestosterone *Endokrinologie* **80** (1982) 163–172
- 45 Tooth M and Zakar T Relative binding affinities of testosterone, 19-nortestosterone and their 5 α -reduced derivatives to the androgen receptor and to other androgen binding proteins a suggested role of 5 α -reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19-nortestosterone *J Steroid Biochem* **17** (1982) 653–660
- 46 Bergink E W, Janssen P S L, Turpijn E W and Van der Vies J Comparison of the receptor binding properties of nandrolone and testosterone under *in vitro* and *in vivo* conditions *J Steroid Biochem* **22** (1985) 831–836
- 47 Bergink E W, Geelen J A A and Turpijn E W Metabolism and receptor binding of nandrolone and testosterone under *in vitro* and *in vivo* conditions *Acta Endocr* **110** (Suppl 271) (1985) 31–38
- 48 Steel R E, Didato F, Sawyer W K and Steinez G B Evidence that 5 α -reduction of Δ 4,3-ketosteroids may be more important for their androgenic than their luteinizing hormone-inhibiting activity *Endocrinology* **105** (1979) 1036–1040
- 49 Wilson J D and Griffin J E The use and misuse of androgens *Metabolism* **29** (1980) 1278–1295
- 50 Max S R and Rance N E No effect of sex steroids on compensatory muscle hypertrophy *J Appl Physiol* **56** (1984) 1589–1593
- 51 Kuhn F E and Max S R Testosterone and muscle hypertrophy in female rats *J Appl Physiol* **59** (1985) 24–27
- 52 Tsika R W, Herrick R E and Baldwin K M Effect of anabolic steroids on overloaded and overloaded suspended skeletal muscle *J Appl Physiol* **63** (1987) 2128–2133
- 53 Bartsch W, Krieg M and Voigt K D Regulation and compartmentalization of androgens in rat prostate and muscle *J Steroid Biochem* **19** (1983) 929–937
- 54 Bates P C, Chew L F and Millward D J Effects of the anabolic steroid stanozolol on growth and protein metabolism in the rat *J Endocr* **114** (1987) 373–381
- 55 Pastoris O, Dossena M, Fulle D, Taglietti M and Benzi G Action of testosterone on some biochemical parameters related to the energy metabolism of the skeletal muscle *Archs Int Pharmacodyn Ther* **263** (1983) 129–132
- 56 Rance N E and Max S R Modulation of the cytosolic androgen receptor in striated muscle by sex steroids *Endocrinology* **115** (1984) 862–866
- 57 Sinnott-Smith P A, Palmer C A and Butterly P J Androgen receptors in skeletal muscle cytosol from sheep treated with trenbolone acetate *Horm Metab Res* **19** (1987) 110–114
- 58 Menschikowski M, Jung K, Junghans P, Petzke K J and Albrecht V The influence of a steroid hormone and of physical exercise on protein metabolism in rats *Exp Clin Endocr* **92** (1988) 341–348
- 59 Morano I and Weicker H The influence of permanent physical stress and metandienone on the degradation of myofibrillar proteins of heart and soleus of Guinea pigs *Arzneim Forsch* **35** (1985) 501–503
- 60 Saborido A, Vila J, Molano F and Megias A Effect of anabolic steroids on mitochondria and sarcotubular system of skeletal muscle *J Appl Physiol* **70** (1991) 1038–1043
- 61 Guzman M, Saborido A, Castro J, Molano F and Megias A Treatment with anabolic steroids increases the activity of the mitochondrial outer carnitin palmitoyltransferase in rat liver and fast-twitch muscle *Biochem Pharmacol* **41** (1991) 833–835
- 62 Fowler W M Jr, Gardner G W and Egstrom G H Effect of anabolic steroid on physical performance of young men *J Appl Physiol* **20** (1965) 1038–1040
- 63 Casner S W Jr, Early R G and Carlson R B Anabolic steroid effects of body composition in normal young men *J Sports Med Phys Fit* **11** (1971) 98–103
- 64 Ariel G and Saville W Anabolic steroids the physiological effects of placebos *Med Sci Sports* **4** (1972) 124–126
- 65 Fahey T D and Brown C H The effects of an anabolic steroid on the strength, body composition, and endurance of college males when accompanied by a weight training program *Med Sci Sports* **5** (1973) 272–276
- 66 Stromme S G, Meen H D and Aakvaag A Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males *Med Sci Sports* **6** (1974) 203–208
- 67 Golding L A, Freyding J E and Fishel S S Weight, size, and strength unchanged with steroids *Physician Sports Med* **2** (1974) 39–43
- 68 Johnson L C, Roundy E D, Allsen P E, Fisher A G and Silvester L J Effect of anabolic steroid treatment on endurance *Med Sci Sports* **7** (1975) 287–289
- 69 Hervey G R, Hutchinson I, Knibbs A V, Burkinshaw L, Jones P R M, Norgan N G and Levell M J “Anabolic” effects of methandienone in men undergoing athletic training *Lancet* **2** (1976) 699–702
- 70 Loughton S J and Ruhling R O Human strength and endurance responses to anabolic steroid and training *J Sports Med* **17** (1977) 285–296
- 71 Crist D M, Stackpole P J and Peake C T Effects of androgenic-anabolic steroids on neuromuscular power and body composition *J Appl Physiol* **54** (1983) 366–370
- 72 Ballarín E, Guglielmi C, Martinelli S, Casoni I, Borsetto C, Ziglio P G and Conconi F Unmodified performance in runners following anabolic steroid administration *Int J Sports Med* **7** (1986) 302–306

- 73 Johnson L C and O'Shea J P Anabolic steroid effects on strength development *Science* **164** (1969) 957-960
- 74 O'Shea J P The effects of an anabolic steroid on dynamic strength levels of weightlifters *Nutr Rep Int* **4** (1971) 363-370
- 75 Johnson L C, Fisher G, Silvester L J and Hofheins C C Anabolic steroid effects on strength, body weight, oxygen uptake and spermatogenesis upon mature males *Med Sci Sports* **4** (1972) 43-45
- 76 Ward P The effects of an anabolic steroid on strength and lean body mass *Med Sci Sports* **5** (1973) 277-282
- 77 Ariel G The effect of anabolic steroid upon skeletal muscle contractile force *J Sports Med* **13** (1973) 187-190
- 78 Ariel G Residual effect of an anabolic steroid upon isotonic muscular force *J Sports Med* **14** (1974) 103-111
- 79 Freed D L J, Banks A J, Longson D and Burley D M Anabolic steroids in athletics crossover double-blind trial on weightlifters *Br Med J* **2** (1975) 471-473
- 80 Win-May M and Mya-Tu M The effect of anabolic steroids on physical fitness *J Sports Med* **15** (1975) 266-271
- 81 Hervey G R, Knibbs A V, Burkinshaw L, Morgan D B, Jones P R M, Chettle D R and Vartsky D Effects of methandienone on the performance and body composition of men undergoing athletic training *Clin Sci* **60** (1981) 457-461
- 82 Lamb D R Anabolic steroids in athletics How well do they work and how dangerous are they? *Am J Sports Med* **12** (1984) 31-38
- 83 Alen M and Hakkinen K Androgenic effects on serum hormones and maximal force development in strength athletes *J Sports Med* **27** (1987) 38-46
- 84 Haupt H A and Rovere G D Anabolic steroids a review of literature *Am J Sport Med* **12** (1984) 469-484
- 85 Alen M and Hakkinen K J Androgenic steroid effects on serum hormones and on maximal force development in strength athletes *J Sports Med* **27** (1987) 38-46
- 86 Holden S C, Calvo R D and Sterling J C Anabolic steroids in athletics *Texas Med* **86** (1990) 32-36
- 87 Kleiner S M Performance-enhancing aids in sport health consequences and nutritional alternatives *J Am Coll Nutr* **10** (1991) 163-176
- 88 Strauss R H and Yesalis C E Anabolic steroids in the athlete *A Rev Med* **42** (1991) 449-457
- 89 American College of Sports Medicine position stand on the use of anabolic-androgenic steroids in sports *Med Sci Sports Exerc* **19** (1987) 534-539
- 90 Rozenek R, Rahe C H, Kohl H H, Marple D N, Wilson G D and Stone M H Physiological responses to resistance-exercise in athletes self-administering anabolic steroids *J Sports Med Phys Fit* **30** (1990) 354-360
- 91 Boone J B, Lambert C P, Flynn M G, Michaud T J, Rodriguez-Zayas J A and Andres F F Resistance exercise effects on plasma cortisol, testosterone and creatinine kinase activity in anabolic-androgenic steroid users *Int J Sports Med* **11** (1990) 293-297
- 92 Sachs B D and Leipheimer R E Rapid effects of testosterone on striated muscle activity in rats *Neuroendocrinology* **48** (1988) 453-458
- 93 Koenig H, Fan C-C, Goldstone A D, Lu C Y and Trout J J Polyamines mediate androgenic stimulation of calcium fluxes and membrane transport in rat heart myocytes *Circ Res* **64** (1989) 415-426
- 94 Hickson R C, Czerwinski S M, Falduto M T and Young A P Glucocorticoid antagonism by exercise and androgenic-anabolic steroids *Med Sci Sports Exerc* **22** (1990) 331-340
- 95 Hickson R C, Ball K L and Falduto M T Adverse effects of anabolic steroids *Med Toxic Averse Drug Exp* **4** (1989) 254-271
- 96 Lenders J W M, Demacker P N M, Vos J A, Jansen P L M, Hoitsma A J, van 't Laar A and Thien T Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders *Int J Sports Med* **9** (1988) 19-23
- 97 Laseter J T and Russel J A Anabolic steroid-induced tendon pathology a review of the literature *Med Sci Sports Exerc* **23** (1991) 1-3
- 98 Brower K J, Eliopoulos G A, Blow F C, Catlin D H and Beresford T P Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters *Am J Psychiat* **147** (1990) 510-512
- 99 Johnson F L The association of oral androgenic-anabolic steroids and life-threatening disease *Med Sci Sports* **7** (1975) 284-286